

Naomi Walsh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3438415/naomi-walsh-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

347
citations

10
h-index

18
g-index

28
ext. papers

404
ext. citations

4.9
avg, IF

2.91
L-index

#	Paper	IF	Citations
27	RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. <i>Cancer Letters</i> , 2011 , 306, 180-9	9.9	73
26	Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. <i>BMC Urology</i> , 2009 , 9, 6	2.2	65
25	Identification of pancreatic cancer invasion-related proteins by proteomic analysis. <i>Proteome Science</i> , 2009 , 7, 3	2.6	54
24	EGFR and HER2 inhibition in pancreatic cancer. <i>Investigational New Drugs</i> , 2013 , 31, 558-66	4.3	21
23	Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development. <i>Scientific Reports</i> , 2020 , 10, 2778	4.9	18
22	Alterations in integrin expression modulates invasion of pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 140	12.8	17
21	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 557-567	9.7	16
20	The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. <i>Investigational New Drugs</i> , 2018 , 36, 581-589	4.3	15
19	Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. <i>Journal of Proteomics</i> , 2008 , 71, 561-71	3.9	15
18	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. <i>BMC Cancer</i> , 2018 , 18, 965	4.8	13
17	7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells. <i>Tumor Biology</i> , 2014 , 35, 6983-97	2.9	10
16	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2019 , 11,	6.6	6
15	Os(II)-Bridged Polyarginine Conjugates: The Additive Effects of Peptides in Promoting or Preventing Permeation in Cells and Multicellular Tumor Spheroids. <i>Inorganic Chemistry</i> , 2021 , 60, 8123-8134	5.1	5
14	Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project. <i>British Journal of Cancer</i> , 2018 , 119, 374-380	8.7	5
13	Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	4
12	Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify to Be Involved in Invasion and Progression of Pancreatic Cancer. <i>Journal of Oncology</i> , 2020 , 2020, 2951921	4.5	3
11	The effects of lapatinib and neratinib on HER2 protein levels in breast cancer cell lines.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 637-637	2.2	2

10	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. <i>Cancer Research</i> , 2020 , 80, 4004-4013	10.1	1
9	Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. <i>Investigational New Drugs</i> , 2020 , 38, 1365-1372	4.3	1
8	Met and HGF inhibition in triple-negative breast cancer cell lines.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1066-1066	2.2	1
7	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 749490	5.7	1
6	Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1219-1222	8.7	1
5	Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma. <i>Journal of Cancer</i> , 2021 , 12, 4672-4685	4.5	0
4	Alternative signalling mechanisms to mediate Braf-Inhibitor resistance in isogenic primary and metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21045-e21045	2.2	
3	Long-term survival outcomes with immune checkpoint inhibitors (ICI) in metastatic uveal melanoma (MUM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21585-e21585	2.2	
2	Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1046-1046	2.2	
1	Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes. <i>Medical Sciences (Basel, Switzerland)</i> , 2022 , 10, 26	3.3	